254 related articles for article (PubMed ID: 21628835)
1. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins.
Imaizumi S; Navab M; Morgantini C; Charles-Schoeman C; Su F; Gao F; Kwon M; Ganapathy E; Meriwether D; Farias-Eisner R; Fogelman AM; Reddy ST
Circ J; 2011; 75(7):1533-8. PubMed ID: 21628835
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
Sherman CB; Peterson SJ; Frishman WH
Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
[TBL] [Abstract][Full Text] [Related]
3. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.
Namiri-Kalantari R; Gao F; Chattopadhyay A; Wheeler AA; Navab KD; Farias-Eisner R; Reddy ST
Biofactors; 2015 May; 41(3):153-9. PubMed ID: 26072738
[TBL] [Abstract][Full Text] [Related]
4. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management.
Shah PK; Chyu KY
Trends Cardiovasc Med; 2005 Nov; 15(8):291-6. PubMed ID: 16297766
[TBL] [Abstract][Full Text] [Related]
6. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides.
Yu R; Yekta B; Vakili L; Gharavi N; Navab M; Marelli D; Ardehali A
Curr Atheroscler Rep; 2008 Apr; 10(2):171-6. PubMed ID: 18417073
[TBL] [Abstract][Full Text] [Related]
7. The promise of apolipoprotein A-I mimetics.
Mendez AJ
Curr Opin Endocrinol Diabetes Obes; 2010 Apr; 17(2):171-6. PubMed ID: 20125002
[TBL] [Abstract][Full Text] [Related]
8. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice.
Schultz JR; Verstuyft JG; Gong EL; Nichols AV; Rubin EM
Nature; 1993 Oct; 365(6448):762-4. PubMed ID: 8413656
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.
Osei-Hwedieh DO; Amar M; Sviridov D; Remaley AT
Pharmacol Ther; 2011 Apr; 130(1):83-91. PubMed ID: 21172387
[TBL] [Abstract][Full Text] [Related]
10. The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit.
Di Bartolo BA; Vanags LZ; Tan JT; Bao S; Rye KA; Barter PJ; Bursill CA
Lipids Health Dis; 2011 Nov; 10():224. PubMed ID: 22128776
[TBL] [Abstract][Full Text] [Related]
11. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.
Moore RE; Navab M; Millar JS; Zimetti F; Hama S; Rothblat GH; Rader DJ
Circ Res; 2005 Oct; 97(8):763-71. PubMed ID: 16151025
[TBL] [Abstract][Full Text] [Related]
12. Focus on high-density lipoproteins in reducing cardiovascular risk.
Brewer HB
Am Heart J; 2004 Jul; 148(1 Suppl):S14-8. PubMed ID: 15211328
[TBL] [Abstract][Full Text] [Related]
13. High-density lipoprotein: antioxidant and anti-inflammatory properties.
Navab M; Yu R; Gharavi N; Huang W; Ezra N; Lotfizadeh A; Anantharamaiah GM; Alipour N; Van Lenten BJ; Reddy ST; Marelli D
Curr Atheroscler Rep; 2007 Sep; 9(3):244-8. PubMed ID: 18241620
[TBL] [Abstract][Full Text] [Related]
14. Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein.
Smith JD
J Clin Lipidol; 2010; 4(5):382-8. PubMed ID: 21076633
[TBL] [Abstract][Full Text] [Related]
15. Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study.
van Capelleveen JC; Bochem AE; Boekholdt SM; Mora S; Hoogeveen RC; Ballantyne CM; Ridker PM; Sun W; Barter PJ; Tall AR; Zwinderman AH; Kastelein JJP; Wareham NJ; Khaw KT; Hovingh GK
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28775061
[TBL] [Abstract][Full Text] [Related]
16. Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of HDL.
Shao B
Biochim Biophys Acta; 2012 Mar; 1821(3):490-501. PubMed ID: 22178192
[TBL] [Abstract][Full Text] [Related]
17. Effect of apolipoprotein A-I lipidation on the formation and function of pre-beta and alpha-migrating LpA-I particles.
Sparks DL; Frank PG; Braschi S; Neville TA; Marcel YL
Biochemistry; 1999 Feb; 38(6):1727-35. PubMed ID: 10026251
[TBL] [Abstract][Full Text] [Related]
18. HDL and Therapy.
Li K; Xie X; Guo Y
Adv Exp Med Biol; 2022; 1377():171-187. PubMed ID: 35575930
[TBL] [Abstract][Full Text] [Related]
19. Structure and function of apolipoprotein A-I and high-density lipoprotein.
Segrest JP; Li L; Anantharamaiah GM; Harvey SC; Liadaki KN; Zannis V
Curr Opin Lipidol; 2000 Apr; 11(2):105-15. PubMed ID: 10787171
[TBL] [Abstract][Full Text] [Related]
20. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.
Amar MJ; D'Souza W; Turner S; Demosky S; Sviridov D; Stonik J; Luchoomun J; Voogt J; Hellerstein M; Sviridov D; Remaley AT
J Pharmacol Exp Ther; 2010 Aug; 334(2):634-41. PubMed ID: 20484557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
